BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AlphaMed Release: MAPCs Bring Lasting Improvements After Brain Injury, Pre-Clinical Study Finds


11/4/2013 10:28:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Durham, NC – A stem cell therapy previously shown to reduce inflammation in the critical time window after traumatic brain injury also promotes lasting cognitive improvement, according to a pre-clinical study reported in the current issue of STEM CELLS Translational Medicine.

Cellular damage in the brain after traumatic injury can cause severe, ongoing neurological impairment and inflammation. Few pharmaceutical options exist to treat the problem. About half of patients with severe head injuries need surgery to remove or repair ruptured blood vessels or bruised brain tissue.

A stem cell treatment known as Multipotent Adult Progenitor Cell (MAPC®) therapy, has been found to reduce inflammation in rats immediately after traumatic brain injury, but no one had yet gauged its usefulness in promoting recovery of neurological function over time. Now, a group of scientists studying that question has come up with a preliminary answer.

A research team led by Charles Cox, Jr., M.D. of the University of Texas Medical School at Houston and scientists from Athersys, Inc., the biotechnology company developing the cellular theraphy, injected two groups of brain-injured rats with MAPC cells two hours after the rats’ brains were injured and again 24 hours later. One group received a dose of 2 million cells per kilogram and the other a dose five times stronger.

After four months, the rats receiving the higher dose not only continued to have less inflammation—they also made significant gains in cognitive function. A laboratory examination of the rodents’ brains confirmed that those receiving the higher dose of MAPC therapy had better brain function than those receiving the lower dose.

“Based on our data, we saw improved spatial learning and motor deficits and reduced inflammation in the rats that were given the stronger concentration of MAPCs,” Dr. Cox said.

The finding indicates that intravenous injection of MAPC therapy may someday become a viable treatment for people with traumatic brain injury, he said.

A Small Business Innovation Research agreement with Athersys, an Ohio biotechnology company developing regenerative therapies, and grants from Brown Foundation Inc. and Children’s Memorial Hermann Hospital Foundation funded the research reported in the study.

“Although preliminary, these findings offer evidence that this cell therapy can attenuate chronic neuro-inflammation and improve long-term cognitive functioning after traumatic brain injury,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

The full article, “Intravenous Multipotent Adult Progenitor Cell Therapy Attenuates Activated Microglial/Macrophage Response and Improves Spatial Learning after Traumatic Brain Injury,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (www.StemCells.com), in its 31th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, in its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES